Taal MW - Search Results

1

Nutritional status assessment: a neglected biomarker in persons with end-stage kidney disease.

Viramontes-Hörner D, Taal MW. Viramontes-Hörner D, et al. Among authors: taal mw. Curr Opin Nephrol Hypertens. 2020 Nov;29(6):547-554. doi: 10.1097/MNH.0000000000000651. Curr Opin Nephrol Hypertens. 2020. PMID: 33009127

2

Evolving strategies for renoprotection: non-diabetic chronic renal disease.

Taal MW, Brenner BM. Taal MW, et al. Curr Opin Nephrol Hypertens. 2001 Jul;10(4):523-31. doi: 10.1097/00041552-200107000-00007. Curr Opin Nephrol Hypertens. 2001. PMID: 11458034 Review.

3

Combination ACEI and ARB therapy: additional benefit in renoprotection?

Taal MW, Brenner BM. Taal MW, et al. Curr Opin Nephrol Hypertens. 2002 Jul;11(4):377-81. doi: 10.1097/00041552-200207000-00001. Curr Opin Nephrol Hypertens. 2002. PMID: 12105385 Review.

4

Predicting initiation and progression of chronic kidney disease: Developing renal risk scores.

Taal MW, Brenner BM. Taal MW, et al. Kidney Int. 2006 Nov;70(10):1694-705. doi: 10.1038/sj.ki.5001794. Epub 2006 Sep 13. Kidney Int. 2006. PMID: 16969387 Free article. Review.

5

Markers of arterial stiffness are risk factors for progression to end-stage renal disease among patients with chronic kidney disease stages 4 and 5.

Taal MW, Sigrist MK, Fakis A, Fluck RJ, McIntyre CW. Taal MW, et al. Nephron Clin Pract. 2007;107(4):c177-81. doi: 10.1159/000110678. Epub 2007 Nov 1. Nephron Clin Pract. 2007. PMID: 17975325

6

How to measure proteinuria?

McIntyre NJ, Taal MW. McIntyre NJ, et al. Among authors: taal mw. Curr Opin Nephrol Hypertens. 2008 Nov;17(6):600-3. doi: 10.1097/MNH.0b013e328313675c. Curr Opin Nephrol Hypertens. 2008. PMID: 18941353 Review.

7

Epidemiology and aetiology of dialysis-treated end-stage kidney disease in Libya.

Alashek WA, McIntyre CW, Taal MW. Alashek WA, et al. Among authors: taal mw. BMC Nephrol. 2012 Jun 8;13:33. doi: 10.1186/1471-2369-13-33. BMC Nephrol. 2012. PMID: 22682181 Free PMC article.

8

Chronic kidney disease 10 years on: what have we learned?

Taal MW. Taal MW. Curr Opin Nephrol Hypertens. 2012 Nov;21(6):607-11. doi: 10.1097/MNH.0b013e328358a30e. Curr Opin Nephrol Hypertens. 2012. PMID: 23010759 Review.

9

Natural history of skeletal muscle mass changes in chronic kidney disease stage 4 and 5 patients: an observational study.

John SG, Sigrist MK, Taal MW, McIntyre CW. John SG, et al. Among authors: taal mw. PLoS One. 2013 May 31;8(5):e65372. doi: 10.1371/journal.pone.0065372. Print 2013. PLoS One. 2013. PMID: 23741490 Free PMC article.

10

Chronic kidney disease in general populations and primary care: diagnostic and therapeutic considerations.

Taal MW. Taal MW. Curr Opin Nephrol Hypertens. 2013 Nov;22(6):593-8. doi: 10.1097/MNH.0b013e328365adf6. Curr Opin Nephrol Hypertens. 2013. PMID: 24104481 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

212 results

Search Page

Filters